| Vol. 4.22 – 19 June, 2020 |
| |
|
|
| Scientists aimed to elucidate the role of the deacetylase Sirt6 in hepatic stellate cell (HSC) activation and liver fibrosis. Gain‐ and loss‐of‐function models were used to study the function of Sirt6 in HSC activation. [Hepatology] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Hepatocyte-specific HuR knockout reduced the expression of APOB, UQCRB, and NDUFB6 in mice, reducing liver lipid transport and ATP synthesis, and aggravating high-fat diet-induced non-alcoholic fatty liver disease. [Nature Communications] |
|
|
|
| Investigators showed that the liver-derived apolipoprotein M (ApoM) protected the lung and kidney from pro-fibrotic insults and that this circulating factor was attenuated in aged mice. Aged mouse hepatocytes exhibited transcriptional suppression of ApoM. [Developmental Cell] |
|
|
|
| Roseotoxin B was shown to possess an improving effect on cholestatic liver fibrosis in bile duct-ligated mice, as proved by histochemical and immunohistochemical staining, hepatic biochemical parameters, and TUNEL apoptotic cell detection in tissue sections. [Cell Death & Disease] |
|
|
|
| Scientists investigated the role and mechanism of hydrazinocurcumin (HZC) in regulating HepG2 cell apoptosis and tumorigenicity, and its synergistic effects with 5-fluorouracil (5-Fu). HepG2 cells were treated with HZC and/or 5-Fu to analyze the possible synergistic effects on cell proliferation, apoptosis and cell cycle distribution in vitro using EdU staining. [Biomedicine & PharmacoTherapy] |
|
|
|
| The authors found that sorafenib treatment increased the proportion of SOX9 positive cells in hepatocellular carcinoma (HCC) cell lines. Overexpression of exogenous SOX9 in HCC increased sorafenib resistance both in vitro and in vivo, whereas down-regulation led to inhibition of sorafenib resistance. [Biomedicine & PharmacoTherapy] |
|
|
|
| Researchers investigated the effects and underlying mechanisms of Asiatic acid from Potentilla chinensis on acute liver injury (ALI). The model of ALI in mice was induced by administration with Lipopolysaccharide/D-Galactosamine. [Biomedicine & PharmacoTherapy] |
|
|
|
| Compared with quiescent hepatic stellate cells (HSCs), activated HSCs (aHSCs) had significantly lower expression of glucose transporter 1, the major glucose transporter in HSCs, and its transcription factor hypoxia-inducible factor 1α, which was markedly increased by astaxanthin in aHSCs. [Life Sciences] |
|
|
|
| The hepatoprotective activity of styphelioidin was tested using the CCl4-challenged HepG2 cell model by measuring alanine aminotransferase and aspartate aminotransferase levels in HepG2 cells treated with styphelioidin for one hour followed by 40 mM CCl4. [Phytochemistry] |
|
|
|
| Scientists investigated the effects of specific microRNA-200a (miR-200a) on hepatocellular carcinoma (HCC) tumor cell growth and effect of doxorubicin-mediated cytotoxicity. Their results showed miR-200a to be downregulated in human HCC and HCC tumor cell lines. [Translational Oncology] |
| |
|
|
|
| Scientists highlight some of the recent chemistry and preclinical advances in this space leading to this large number of clinical candidates against a diverse range of targets in liver hepatocytes. [Molecular Therapy] |
|
|
|
|
| Inventiva are developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses and other diseases with significant unmet medical need. They have announced positive topline results from the Phase IIb NAsh Trial to Validate IVA337 Efficacy (NATIVE) clinical trial evaluating lanifibranor for the treatment of NASH. [Inventiva] |
|
|
|
| A bipartisan group of US senators proposed sweeping—and controversial—changes in how the federal government manages academic research in the face of threats from other countries. [ScienceInsider] |
|
|
|
|
| 2020-07-16 – 2020-07-17 Virtual |
|
|
|
|
|
| Columbia University Medical Center – New York, New York, United States |
|
|
|
| Beam Therapeutics – Cambridge, Massachusetts, United States |
|
|
|
| University of Kansas Medical Center – Kansas City, Missouri, United States |
|
|
|
| Ma Lab at University of Pittsburgh – Pittsburgh, Pennsylvania, United States |
|
|
|
| University of Strasbourg – Strasbourg, France |
|
|
|
| Spark Therapeutics – Philadelphia, Pennsylvania, United States |
|
|
|
| The University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| University of Southern California – Los Angeles, California, United States |
|
|
|
| University of New Mexico Comprehensive Cancer Center – Albuquerque, New Mexico, United States |
|
|
|
| Texas Biomedical Research Institute – San Antonio, Texas, United States |
|
|
|
| The University of Hong Kong – Hong Kong, China |
|
|
|
|